Canbridge Pharmaceuticals Inc
Company Profile
Business description
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.
Contact
No. 388 Xinping Street
Unit 18, 6th Floor, Building 21, Suzhou Industrial Park
Pilot Free Trade Zone
Jiangsu Province
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
67
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.00 | 23.70 | -0.27% |
| CAC 40 | 7,741.07 | 34.83 | -0.45% |
| DAX 40 | 23,714.20 | 234.70 | -0.98% |
| Dow JONES (US) | 42,865.77 | 1.10 | -0.00% |
| FTSE 100 | 8,859.11 | 5.24 | -0.06% |
| HKSE | 24,035.38 | 331.56 | -1.36% |
| NASDAQ | 19,615.88 | 99.11 | -0.50% |
| Nikkei 225 | 38,173.09 | 248.10 | -0.65% |
| NZX 50 Index | 12,649.10 | 43.17 | 0.34% |
| S&P 500 | 6,022.24 | 16.57 | -0.27% |
| S&P/ASX 200 | 8,565.10 | 27.00 | -0.31% |
| SSE Composite Index | 3,402.66 | 0.34 | 0.01% |